Latest Health News

Future Generation Global Limited reported a 50% drop in net profit for 2025 but maintained strong investment portfolio growth and declared a special fully franked dividend, while continuing its significant social impact contributions.

Clarity Pharmaceuticals has reported a steep 136% increase in its half-year loss to $55.6 million, alongside the closure of its European subsidiary, signaling a challenging period for the ASX-listed biotech.

Lumos Diagnostics reported a 74% increase in its half-year loss to US$4.88 million, despite strong progress with its FebriDx diagnostic test and a landmark US distribution agreement. The company awaits a critical FDA decision that could unlock significant revenue growth.

6K Additive, a US-based metal powder innovator, reports a 3.85% revenue dip to US$17.7 million and narrows net loss to US$17.9 million in its first ASX-listed year. The company plans a fivefold capacity expansion backed by significant government grants and a US$27.4 million loan.

Entropy Neurodynamics reports a 14.8% reduction in half-year losses while progressing a pioneering clinical trial for Binge Eating Disorder using its proprietary psychedelic drug TRP-8803. The company also secured $6.1 million in new funding and strategic collaborations to enhance its neuropsychiatry platform.

Jupiter Mines Limited reported a 15.7% rise in profit after tax for HY2026, driven by its stake in the Tshipi manganese mine and a key joint venture deal with Exxaro Resources. The company navigates production challenges and market shifts while preparing for a dividend decision.

4DMedical Limited’s half-year report reveals rapid commercial traction following FDA clearance of its CT:VQ™ imaging technology, alongside a $150 million institutional placement that bolsters its cash reserves for global expansion.

Metals X Limited reported a robust 2025 financial year with revenue up 30% to $285 million, driven by higher tin prices despite a slight dip in production. The company is advancing its key growth project, Rentails, targeting a final investment decision in late 2026.

Dataworks Group Limited reported a significant reduction in its half-year loss alongside a major contract extension in Ontario, marking a pivotal shift to positive cash flow.

Frontier Energy Limited has reported a sharp 71% increase in net loss for the year ended 31 December 2025, with no dividends declared and a slight dip in net tangible assets per share.

Atlas Pearls reports a challenging first half of FY26 with a 27% drop in revenue and a net loss of $5.2 million, driven by weaker market demand and a shift towards lower-grade pearl sales.

Emyria Limited has reported a significant 136% increase in revenue to $1.55 million for the half-year ended December 2025, driven by its expanding Empax clinic network and insurer-funded treatments across Australia. Despite this growth, the company posted a $2.37 million net loss, reflecting investments in scaling operations and infrastructure.